Markers of GB virus C (GBV-C) and hepatitis C virus (HCV) were sought in 80 patients before and after they underwent BMT in a metropolitan hospital in Tokyo between 1990 and 1996. RNA of GBV-C was detected in 14 (18%) patients before BMT. Of the 55 patients who had been transfused, 14 (25%) possessed GBV-C RNA at a frequency significantly higher than in the 25 untransfused patients who were all negative (P Ͻ 0.01). HCV RNA was detected in three of the 55 (5%) transfused patients, but in none of the 25 untransfused patients. Sera at 3 months after BMT were available for 57 patients. GBV-C RNA persisted in all 10 patients who were infected before BMT, while it was detected in five of the remaining 47 (11%) patients who were not. However, persistent and/or ongoing GBV-C infection had no appreciable influence on patient morbidity or mortality. Two of the 57 patients were positive for HCV RNA before BMT and this persisted after BMT in both. HCV RNA became positive in eight of the remaining 55 (15%) patients who were negative before BMT. Of the 14 patients who received transfusions screened by the first-generation test at BMT, seven (50%) became positive for HCV RNA, a rate significantly higher than the one of 41 (2%) patients who received transfusions screened by the second-generation test (P Ͻ 0.001). These results indicate that BMT patients are at increased risk of GBV-C infection transmitted by transfusions received before and at the time of BMT, and that the risk of HCV infection has decreased after the implementation of the second-generation anti-HCV test. Keywords: GBV-C; HCV; BMT Patients undergoing BMT are at increased risk of infection with blood-borne hepatitis viruses such as hepatitis B virus (HBV) and hepatitis C virus (HCV), which poses serious problems.
bone marrow donors. Since most patients have underlying diseases impairing their immune system and receive myeloablative therapies before BMT, infection with hepatitis viruses tends to persist and may induce severe hepatitis. Furthermore, the infection may be modulated by the adoptive immunity transferred by a bone marrow donor who has been infected or who has overcome the infection.
Recently, a putative hepatitis virus designated GB virus C (GBV-C) or hepatitis G virus (HGV) has been discovered. 2, 3 For the sake of convenience these are collectively referred to here as GBV-C. This is a positive, singlestranded RNA virus of approximately 9400 bases and classified in the Flaviviridae family. GBV-C prevails worldwide, as estimated by the detection of its RNA in 1-5% of apparently healthy blood donors. [3] [4] [5] [6] [7] GBV-C is transmited by transfusion and intravenous drug abuse. 5, [8] [9] [10] [11] Coinfection with GBV-C and HBV or HCV is frequent in patients with chronic liver disease and in intravenous drug users. 3, 8 GBV-C infection persists in patients with compromised immunity, such as those on maintenance hemodialysis. 5 The ability of GBV-C to induce hepatitis has, however, as yet, not been established.
Evidence of infection with GBV-C, HCV and HBV was sought in patients with malignant hematological diseases or aplastic anemia before and after they underwent BMT, and the results were correlated with the number of transfusions they received before and at the time of transplantation.
Patients and methods

Study population
From July 1990 to August 1996, a total of 155 patients underwent BMT in the Hematology Division of Tokyo Metropolitan Komagome Hospital. Only the patients who underwent allogeneic BMT and whose pre-BMT sera are available were included in this retrospective study. One hundred and twenty-four patients received allogeneic or syngeneic BMT and in 80 patients, pre-BMT sera were available (Table 1) . They included 44 males and 36 females with the mean (Ϯs.d.) age of 32 (Ϯ9) years.
During BMT, complete blood counts were performed three times a week and blood chemistries obtained two to three times a week. Patients were evaluated retrospectively for veno-occlusive disease (VOD) by the criteria of McDonald et al, 12 GVHD, graft rejection, interstitial pneumonia, hemorrhagic cystitis and varicella zoster virus infection. In 57, sera 3 months after BMT were also available, while in 23 patients, follow-up sera were not available even though all survived for more than 3 months after BMT.
Bone marrow transplantation
Preparative therapy was given mainly according to the primary diseases and source of bone marrow. Patients with AML and CML were treated with busulfan 16 mg/kg and cyclophosphamide 120 mg/kg (BU/CY). Total lymphoid irradiation (TLI) was added in patients who received marrow from unrelated donors. Patients with severe aplastic anemia were treated with cyclophosphamide 200 mg/kg and TLI 700 cGy (CY/TLI) and those with ALL were treated with Ara-C 8 g/m 2 and cyclophosphamide 120 mg/kg, followed by total body irradiation (TBI), 1200 cGy (Ara-C/CY/TBI). Other diseases were treated with BU/CY or Ara-C/CY/TBI.
All patients except for those undergoing syngeneic BMT received cyclosporine and short-term methotrexate as prophylaxis for GVHD.
Determination of GBV-C RNA
RNAs were extracted from 100 l of serum with an extraction reagent containing guanidinium isothiocyanate and phenol (ISOGEN-LS; Nippon Gene Co. Ltd, Tokyo, Japan) and dissolved in 5.3 l of distilled water treated with diethylpyrocarbonate (Sigma Chemical, St Louis, MO, USA). Samples were reverse transcribed and the cDNA was amplified by PCR using primers taken from well-conserved areas in the 5′ untranslated region of the genome, by the method described previously. 9 For semi-quantitative analysis of GBV-C RNA, serial samples of 10-fold dilution of extracted RNAs were prepared, and the sample of the highest dilution positive for GBV-C RNA was determined. The result was converted to represent the titer (10 N ) of the virus per ml of the test serum.
Markers of HCV and HBV infections
Until January 1992, blood transfused to patients was screened for antibody to HCV (anti-HCV) by the first-generation enzyme-linked immunosorbent assay (ELISA) using Ortho ELISA I (Ortho Diagnostic Systems, Tokyo, Japan) and thereafter by the second-generation ELISA (Ortho ELISA II; Ortho Diagnostic Systems).
Sera from patients were serially diluted two-fold, and anti-HCV was assayed by hemagglutination using Abbott HCV PHA 2nd Generation (Dainabot, Tokyo, Japan). Sera inducing hemagglutination at dilutions Ͼ2 5 were considered to be positive for anti-HCV. RNA of HCV was determined in RNAs extracted from 100 l of the test serum by a commercial kit (Amplicor HCV detection kit; Japan Roche, Tokyo, Japan).
Hepatitis B surface antigen (HBsAg) and the corresponding antibody (anti-HBs) were determined by serial two-fold dilutions of the test serum using commercial kits (MyCell; Institute of Immunology Co. Ltd, Tokyo, Japan), and hemagglutination at dilutions у2 2 was considered reactive.
Statistical analysis
Frequencies between groups were compared with the 2 test or Fisher's exact test using StatView (Abacus Concepts, Berkeley, CA, USA). Group means were compared using the Student's t-test. Table 2 gives prevalence rates of viral markers in the 80 patients before BMT. GBV-C RNA was detected in 14 (18%) patients, HCV RNA in three (4%) and HBsAg in none (P Ͻ 0.001). No patients were vaccinated against HBV. All three patients with HCV RNA were positive for Table 2 Markers of GB virus C, hepatitis C virus and hepatitis B virus infections in patients before BMT
Results
GBV-C, HCV and HBV markers before BMT
Viral markers
Total Transfusion P value a n = 80 (%)
a Compared between the patients with previous transfusions and those without.
anti-HCV; no patients had seronegative HCV infection. Previously transfused patients had a higher frequency of GBV-C RNA than untransfused patients (14 of 55 or 25% vs none of 25 or 0%, P Ͻ 0.01). All three patients with HCV RNA had received transfusions; two of these were positive for GBV-C RNA. RNAs of GBV-C and HCV in patients with various underlying diseases are shown in Table 3 , with special reference to the number of transfused units (best estimated number of exposures to blood donors) they had received. All 13 patients with AML had received 50 or more units of blood, of whom 10 (77%) had GBV-C RNA and two were positive for HCV RNA. Both also possessed GBV-C RNA. In contrast, of 21 patients with other diseases who had received у50 units, only two (10%) were positive for GBV-C RNA (P Ͻ 0.001). However, patients with diseases other than AML had received rather fewer blood units (mean Ϯ s.d.: 143 Ϯ 84 vs 322 Ϯ 292 units).
Only two of the 21 (10%) patients who had received Ͻ50 units possessed GBV-C RNA, and neither were positive for HCV RNA.
Effects of GBV-C on BMT patients
VOD occurred in none of the 14 patients with GBV-C RNA, and in six of the 66 (9%) patients without (P = 0.32). In the 14 patients with GBV-C, the mean of the maximum levels of total bilirubin during the first 3 months was 0.9 mg/dl (0.4-2.1) ( Table 4) . Serum alanine aminotransferase (ALT) levels were within three times the normal range up to 20 days after BMT in all but two patients and within twice the usual range between day 20 and 3 months in all but two patients. There were no differences in the incidence of graft-versus-host disease, graft rejection, interstitial pneumonia, hemorrhagic cystitis and varicella zoster virus infection between patients with and without GBV-C RNA. No differences were observed in recovery of WBC to Ͼ1 × 10 9 /l, reticulocytes Ͼ0.5% and platelets Ͼ50 × 10 9 /l, or in the period during which platelet transfusions were required (data not shown).
Table 3
Prevalence rates of GBV-C RNA and HCV RNA in patients stratified by disease and number of blood units before BMT 
GBV-C RNA in patients after BMT
In 57 of 80 patients, sera obtained at 3 months after BMT were also available. GBV-C RNA persisted in all 10 patients who had it before BMT. Five of the remaining 47 (11%) patients who were negative for GBV-C RNA before BMT acquired it after BMT (de novo infection) ( Table 5) . In those five patients, ALT levels before BMT were within normal limits (Ͻ40 IU/l), but they increased in three patients after BMT, one of whom was coinfected with HCV and had the highest ALT level. Titers of GBV-C RNA ranged from 10 1 /ml to у10 4 /ml in these patients but there was no correlation between RNA titer and level of ALT. Their maximum total bilirubin levels were less than 1.4 mg/dl at 3 months and no patients developed VOD.
All 57 patients received transfusions during the course of BMT (total: 931 units). There were no differences in the numbers of blood units received between the five patients who contracted de novo GBV-C infection and the 42 patients who did not (16 Ϯ 11 vs 14 Ϯ 11).
HCV infection in patients after BMT
Of the 57 patients whose sera were available at 3 months after BMT, two possessed HCV RNA before BMT which persisted. HCV RNA became positive in eight of the remaining 55 (15%) patients (Table 6 ). After BMT, ALT levels increased in seven to higher levels than before BMT. A moderately elevated level of ALT (60 IU/l) in the remaining one patient (Patient No. 51) decreased to normal after BMT. Anti-HCV antibody became detectable in seven, while one other patient became positive for anti-HCV antibody without HCV RNA.
Blood products were screened for HCV by the firstgeneration ELISA before February 1992 when the secondgeneration ELISA was implemented. Of the 55 patients without pre-transplantation HCV RNA, 14 had received transfusions at BMT screened by the first-generation ELISA, and eight (57%) of these became positive for HCV RNA after BMT. By contrast, none of the 41 transfused patients screened by the second-generation ELISA developed HCV RNA at a significantly lower frequency (P Ͻ 0.001).
Discussion
GBV-C was detected in 14 of the 80 (18%) BMT patients whose sera were available. In addition, RNA of GBV-C became detectable in five of the 47 (11%) patients within 3 months of BMT. Inclusive of the 10 patients who were infected before BMT, 15 of the 57 patients (26%) were positive for GBV-C RNA after BMT. The frequency of GBV-C infection in the BMT patients was much higher than in the general population of Japan, which is reported as 1.2%. 13 Hence, patients undergoing BMT are at increased risk for GBV-C infection, as was the case for HBV and HCV before screening and exclusion of contaminated blood units. 1 These results confirm a recent report from the UK documenting the detection of HGV RNA in 20 of 33 (61%) recipients of BMT 14 and a report of 42% from Spain. 15 H Akiyama et al 1134 ALT, alanine aminotransferase (normal: Ͻ40 IU/l). None of the blood units or bone marrow donors were tested for GBV-C RNA. However, there is evidence to indicate transmission of GBV-C to patients by transfusions they received before and during BMT. Before BMT, GBV-C RNA was detected significantly more frequently in patients who had received transfusions than in those who had not (25 vs 0%, P Ͻ 0.01). Furthermore, GBV-C RNA was detected more frequently in patients with AML who received more units of blood before BMT than in patients with the other diseases (77 vs 10%, P Ͻ 0.001).
The incidence of VOD was not raised in patients with GBV-C, and neither was the incidence of severe liver damage during the first 3 months after BMT. Maximum levels of ALT were within three times the normal range and the maximum levels of total bilirubin during the 3 months were less than 2.1 mg/dl in patients with GBV-C, suggesting an insignificant association between GBV-C and acute liver toxicity, which is also consistent with previous reports. 14, 15 At BMT, 657 blood units (plus 47 bone marrow donations) were given to the 47 patients negative for GBV-C RNA. Assuming 1.2% of blood donors were infected with GBV-C, at least eight contaminated blood units were transfused.
ALT levels after BMT increased in three of the five (60%) patients who acquired GBV-C RNA. One of the three patients with GBV-C RNA, however, became positive for HCV RNA which could have been responsible for the elevated ALT. ALT levels were within three times the normal range at most in these patients. In view of a variety of factors potentially inducing impaired liver function in recipients of BMT, elevated ALT levels in the two patients infected with GBV-C cannot readily be ascribed only to GBV-C. 1 On the other hand, HCV RNA is a more reliable marker of HCV infection than is anti-HCV in BMT patients, since impaired immune responses can prevent seroconversion. HCV RNA became detectable in eight patients after BMT and one of these was negative for anti-HCV. HCV RNA was detected in the recipients of blood units screened by the first-generation anti-HCV ELISA significantly more frequently than in those screened by the second-generation anti-HCV ELISA (57 vs 0%, P Ͻ 0.001). Thus, HCV infection in recipients of BMT appears to have decreased as the sensitivity of the tests increases.
These results indicate that patients with BMT are at increased risk for GBV-C infection transmitted to them by transfusions they receive before and at the time of BMT, and that the risk of HCV infection has decreased after the implementation of the second-generation anti-HCV test. All in all, there were no appreciable effects of persistent and/or ongoing GBV-C infection on the morbidity or mortality in the patients who underwent BMT.
